Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029529 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
A Phase 2 study, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT07029529 is a Phase 2 study that is actively recruiting participants, run by Yale University. The registered enrollment target is 80 participants.
The verdict
NCT07029529, a Phase 2 study, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
For this protocol, the investigators plan to collect data to evaluate apremilast (60mg/day) vs placebo in adults with Alcohol Use Disorders (AUD).
Interventions
- OTHER Placebo
- DRUG Apremilast 60mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-05-12 |
| Est. Completion | 2030-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029529
The ClinicalTrials.gov registry entry for NCT07029529 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07029529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07029529 about?
NCT07029529 is a clinical study titled "Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder". For this protocol, the investigators plan to collect data to evaluate apremilast (60mg/day) vs placebo in adults with Alcohol Use Disorders (AUD).
What is the current status of trial NCT07029529?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-05-12. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07029529?
The interventions under investigation include: Placebo (OTHER), Apremilast 60mg (DRUG).
Who is sponsoring clinical trial NCT07029529?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.